Stealth BioTherapeutics, a US-based mitochondrial dysfunction biotech in clinical trials, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Newton, MA-based company was founded in 2006 and plans to list on the Nasdaq under the symbol MITO. Stealth BioTherapeutics filed confidentially on October 26, 2018. Jefferies, Evercore ISI and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
